ClinicalTrials.gg
CompletedNCT02441946neoMONARCHUpdated Jun 17, 2020Results posted

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

A Phase 2 interventional study of Abemaciclib and Loperamide in Breast Cancer, Hormone Receptor Positive Tumor and Early-Stage Breast Carcinoma, sponsored by Eli Lilly and Company. Completed at 66 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
14th of 55
224 · median 120
Started
2015
with 1 other
Phase 2
27 of 55
12 open now
Registered
6th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2015, is one of 27 in phase 2, and was the 6th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the biological effects of abemaciclib in combination with anastrozole and compare those to the effects of abemaciclib alone and anastrozole alone in the tumors of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer.

03

Conditions studied

  • Breast Cancer
  • Hormone Receptor Positive Tumor
  • Early-Stage Breast Carcinoma

Browse trials for

Keywords

  • cyclin-dependent kinase (CDK) 4/6 inhibitor
  • CDK 4 and 6 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have status.
  • Adenocarcinoma of the breast.
  • Breast tumor ≥1 centimeter (cm) in diameter, HR+, -.
  • endocrine monotherapy is deemed to be a suitable therapy.
  • Primary breast cancer that is suitable for baseline core .
  • Have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Bilateral invasive breast cancer.
  • breast cancer (local spread to axillary lymph nodes is permitted).
  • Inflammatory breast cancer.
  • Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated.
  • Prior radiotherapy to the ipsilateral chest wall for any .
  • Prior anti-estrogen therapy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Abemaciclib + Anastrozole

    Abemaciclib (150 milligrams \[mg\]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion. All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.

    Drug: Abemaciclib · Drug: Loperamide · Drug: Anastrozole

  • Experimental
    Abemaciclib

    Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion. All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks.

    Drug: Abemaciclib · Drug: Loperamide · Drug: Anastrozole

  • Active comparator
    Anastrozole

    Anastrozole (1 mg) is given orally QD for 2 weeks. All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks.

    Drug: Abemaciclib · Drug: Loperamide · Drug: Anastrozole

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to 2 Weeks in Ki67 Expression

    Tumor tissue collected through a core biopsy at baseline and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percent of cells staining positive by validated central assay.

    Time frame: Baseline, 2 Weeks

Secondary outcomes

  1. Percentage of Participants With Pathologic Complete Response (pCR)

    pCR is defined as absence of invasive cancer in the breast and sampled regional lymph nodes.

    Time frame: From Start of Treatment Up to 16 Weeks

  2. Percentage of Participants With Complete Response (CR) or Partial Response (PR): Clinical Objective Response

    Clinical objective response is defined as the percentage of participants with the best overall response rate (ORR) with a best OR of CR or PR, according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1. ORR is recorded from the start of the study treatment until the earliest of objective progression or start of new anticancer therapy. A responder depends on target and non-target disease and the appearance of new lesions. CR is defined as the disappearance of all non-target lesions. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. All lymph nodes are non-pathological or normal in size (\<10mm short axis). Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, a relative increase of 20%, the sum must also demonstrate an absolute increase of 5 mm.

    Time frame: From Start of Treatment to Objective Progression or Start of New Anticancer Therapy (Up to 16 Weeks)

  3. Percentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response

    Radiological response is the percentage of participants with CR or, PR according to RECIST v.1.1. A responder is defined as any participant who exhibits a CR or PR. CR is the disappearance of all target lesions. PR is a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. PD is 20% increase in the sum of diameters of target lesions taking as reference the smallest sum and the appearance of 1 or more new lesions.

    Time frame: From Start of Treatment to Objective Progression or Start of New Anticancer Therapy (Up to 16 Weeks)

  4. Change From Baseline to Week 2 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, emotional, cognitive, or social functioning), global health status and symptom scales of fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.

    Time frame: Baseline, 2 Weeks

  5. Pharmacokinetics (PK): Apparent Clearance of Abemaciclib

    Abemaciclib apparent clearance (CL/F) was calculated by population nonlinear mixed effects modeling (NONMEM) using all available data spanning cycles 1 and cycles 3-5.

    Time frame: Cycle(C)1, Day(D)1: 2 to 4 Hours (Hrs) Postdose; C1D14: 4 Hrs Postdose, 7 Hrs Postdose; C3D1: Predose, 3 Hrs Postdose, C4D1 & C5D1, Predose, C5D28: Predose, 3 Hrs Postdose

  6. PK: Apparent Volume of Distribution of Abemaciclib

    Abemaciclib apparent volume of distribution was calculated by population NONMEM using all available data spanning cycles 1 and cycles 3-5.

    Time frame: Cycle(C)1, Day(D)1: 2 to 4 Hours (Hrs) Postdose; C1D14: 4 Hrs Postdose, 7 Hrs Postdose; C3D1: Predose, 3 Hrs Postdose, C4D1 & C5D1, Predose, C5D28: Predose, 3 Hrs Postdose

07

Results

Posted Jan 30, 2018

Participant flow

Cycle 1 Period 1 (2 Weeks)
Participant flow — Cycle 1 Period 1 (2 Weeks)
MilestoneAbemaciclib + AnastrozoleAbemaciclibAnastrozole
Started747674
Received at least one dose of study drug747574
Completed727174
Not completed250
Withdrew: Adverse event110
Withdrew: Physician decision100
Withdrew: Withdrawal by subject030
Withdrew: Never treated010
Cycle 2-5 Period 2 (14 Weeks)
Participant flow — Cycle 2-5 Period 2 (14 Weeks)
MilestoneAbemaciclib + AnastrozoleAbemaciclibAnastrozole
Started21700
Received at least one dose of study drug21700
Progressive disease500
Completed19000
Not completed2700
Withdrew: Adverse event1500
Withdrew: Noncompliance with study drug100
Withdrew: Physician decision100
Withdrew: Protocol deviation100
Withdrew: Withdrawal by subject900
Extension Period (8 Weeks)
Participant flow — Extension Period (8 Weeks)
MilestoneAbemaciclib + AnastrozoleAbemaciclibAnastrozole
Started4200
Completed4000
Not completed200
Withdrew: Adverse event100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryPercent Change From Baseline to 2 Weeks in Ki67 Expression

Tumor tissue collected through a core biopsy at baseline and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percent of cells staining positive by validated central assay.

Time frame:
Baseline, 2 Weeks
Reported as:
Geometric mean · Percent Change
Percent Change From Baseline to 2 Weeks in Ki67 Expression
Percent ChangeAbemaciclib + AnastrozoleAbemaciclibAnastrozole
Percent Change From Baseline to 2 Weeks in Ki67 Expression-92.86 (-94.82 to -90.16)-90.52 (-93.12 to -86.93)-62.78 (-72.99 to -48.71)
Statistical analysis
  • Abemaciclib + Anastrozole vs Anastrozole · t-test, 1 sided · p = <0.001 · Ratio of geometric means: 0.19 · 90% CI 0.13 to 0.28
  • Abemaciclib vs Anastrozole · t-test, 1 sided · p = <0.001 · Ratio of geometric means: 0.25 · 90% CI 0.17 to 0.38
SecondaryPercentage of Participants With Pathologic Complete Response (pCR)

pCR is defined as absence of invasive cancer in the breast and sampled regional lymph nodes.

Time frame:
From Start of Treatment Up to 16 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Pathologic Complete Response (pCR)
percentage of participantsAbemaciclib + Anastrozole
Percentage of Participants With Pathologic Complete Response (pCR)3.7
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR): Clinical Objective Response

Clinical objective response is defined as the percentage of participants with the best overall response rate (ORR) with a best OR of CR or PR, according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) v1.1. ORR is recorded from the start of the study treatment until the earliest of objective progression or start of new anticancer therapy. A responder depends on target and non-target disease and the appearance of new lesions. CR is defined as the disappearance of all non-target lesions. PR is at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. All lymph nodes are non-pathological or normal in size (\<10mm short axis). Progressive disease (PD) is a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, a relative increase of 20%, the sum must also demonstrate an absolute increase of 5 mm.

Time frame:
From Start of Treatment to Objective Progression or Start of New Anticancer Therapy (Up to 16 Weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR): Clinical Objective Response
percentage of participantsAbemaciclib + Anastrozole
Percentage of Participants With Complete Response (CR) or Partial Response (PR): Clinical Objective Response53.6
SecondaryPercentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response

Radiological response is the percentage of participants with CR or, PR according to RECIST v.1.1. A responder is defined as any participant who exhibits a CR or PR. CR is the disappearance of all target lesions. PR is a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters. PD is 20% increase in the sum of diameters of target lesions taking as reference the smallest sum and the appearance of 1 or more new lesions.

Time frame:
From Start of Treatment to Objective Progression or Start of New Anticancer Therapy (Up to 16 Weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response
percentage of participantsAbemaciclib + Anastrozole
Percentage of Participants With Complete Radiologic Response or Partial Radiological Response: Radiological Response46.4
SecondaryChange From Baseline to Week 2 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures 5 functional domains (physical, role, emotional, cognitive, or social functioning), global health status and symptom scales of fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, or financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.

Time frame:
Baseline, 2 Weeks
Reported as:
Mean · units on a scale
Change From Baseline to Week 2 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
units on a scaleAbemaciclib + AnastrozoleAbemaciclibAnastrozole
Global Health Status-9.5 ± 17.9-7.6 ± 18.1-2.3 ± 13.4
Physical Functioning-3.2 ± 10.2-5.5 ± 12.6-0.3 ± 7.5
Role Functioning-11.3 ± 23.7-11.4 ± 24.0-2.2 ± 17.4
Emotional5.4 ± 17.13.5 ± 21.41.3 ± 14.0
Cognitive0.5 ± 12.4-2.0 ± 15.6-1.4 ± 11.0
Social Functioning-8.3 ± 18.8-3.5 ± 16.7-0.7 ± 12.6
Fatigue13.6 ± 23.213.9 ± 22.64.0 ± 12.8
Nausea/Vomiting11.8 ± 17.79.6 ± 12.42.7 ± 7.4
Pain4.8 ± 19.93.5 ± 19.32.9 ± 16.7
Dyspnea1.1 ± 19.10.5 ± 19.8-1.0 ± 12.7
Insomnia-1.1 ± 19.10.5 ± 29.5-1.9 ± 22.1
Appetite Loss16.9 ± 28.316.9 ± 27.51.9 ± 15.0
Constipation22.4 ± 31.516.9 ± 31.21.9 ± 15.0
Diarrhea18.3 ± 29.427.8 ± 25.90.0 ± 15.1
Financial Impact-2.8 ± 19.72.0 ± 18.40.0 ± 11.4
SecondaryPharmacokinetics (PK): Apparent Clearance of Abemaciclib

Abemaciclib apparent clearance (CL/F) was calculated by population nonlinear mixed effects modeling (NONMEM) using all available data spanning cycles 1 and cycles 3-5.

Time frame:
Cycle(C)1, Day(D)1: 2 to 4 Hours (Hrs) Postdose; C1D14: 4 Hrs Postdose, 7 Hrs Postdose; C3D1: Predose, 3 Hrs Postdose, C4D1 & C5D1, Predose, C5D28: Predose, 3 Hrs Postdose
Reported as:
Geometric mean · Liters/hour (L/h)
Pharmacokinetics (PK): Apparent Clearance of Abemaciclib
Liters/hour (L/h)Abemaciclib + AnastrozoleAbemaciclibAnastrozole
Pharmacokinetics (PK): Apparent Clearance of Abemaciclib24.0 ± 3219.1 ± 5524.4 ± 61
SecondaryPK: Apparent Volume of Distribution of Abemaciclib

Abemaciclib apparent volume of distribution was calculated by population NONMEM using all available data spanning cycles 1 and cycles 3-5.

Time frame:
Cycle(C)1, Day(D)1: 2 to 4 Hours (Hrs) Postdose; C1D14: 4 Hrs Postdose, 7 Hrs Postdose; C3D1: Predose, 3 Hrs Postdose, C4D1 & C5D1, Predose, C5D28: Predose, 3 Hrs Postdose
Reported as:
Geometric mean · Liters (L)
PK: Apparent Volume of Distribution of Abemaciclib
Liters (L)Abemaciclib + AnastrozoleAbemaciclibAnastrozole
PK: Apparent Volume of Distribution of Abemaciclib941 ± 53720 ± 58758 ± 49

Adverse events

Collected over Up to 24 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib + Anastrozole Cycle 1—1/74 (1.4%)62/74 (83.8%)
Abemaciclib Cycle 1—1/75 (1.3%)58/75 (77.3%)
Anastrozole Cycle 1—0/74 (0%)17/74 (23%)
Abemaciclib + Anastrozole Cycle 2 and Beyond—16/217 (7.4%)189/217 (87.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventAbemaciclib + Anastrozole Cycle 1Abemaciclib Cycle 1Anastrozole Cycle 1Abemaciclib + Anastrozole Cycle 2 and Beyond
FractureInjury, poisoning and procedural complications0/740/750/743/217
Abdominal painGastrointestinal disorders1/740/750/741/217
Alanine aminotransferase increasedInvestigations1/740/750/740/217
Aspartate aminotransferase increasedInvestigations1/740/750/740/217
Decreased appetiteMetabolism and nutrition disorders0/741/750/740/217
MastitisInfections and infestations0/740/750/742/217
Blood creatinine increasedInvestigations0/740/750/742/217
NeutropeniaBlood and lymphatic system disorders0/740/750/741/217
Acute coronary syndromeCardiac disorders0/740/750/741/217
Angina pectorisCardiac disorders0/740/750/741/217
Most frequent other events
Showing 10 of 24
Most frequent other events
EventAbemaciclib + Anastrozole Cycle 1Abemaciclib Cycle 1Anastrozole Cycle 1Abemaciclib + Anastrozole Cycle 2 and Beyond
DiarrhoeaGastrointestinal disorders31/7429/752/74101/217
ConstipationGastrointestinal disorders27/7426/755/7450/217
NauseaGastrointestinal disorders19/7415/752/7467/217
FatigueGeneral disorders19/7417/753/7462/217
NeutropeniaBlood and lymphatic system disorders2/741/750/7445/217
Abdominal painGastrointestinal disorders13/747/752/7430/217
Decreased appetiteMetabolism and nutrition disorders5/7413/750/7433/217
AnaemiaBlood and lymphatic system disorders0/743/750/7427/217
Alanine aminotransferase increasedInvestigations4/741/750/7426/217
VomitingGastrointestinal disorders5/741/750/7425/217

Baseline characteristics

Age, Continuous
Age, Continuous(years)Abemaciclib + AnastrozoleAbemaciclibAnastrozoleTotal
Mean63.9 ± 8.463.8 ± 7.964.9 ± 8.464.2 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib + AnastrozoleAbemaciclibAnastrozoleTotal
Female747674224
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib + AnastrozoleAbemaciclibAnastrozoleTotal
Hispanic or Latino68519
Not Hispanic or Latino616160182
Unknown or Not Reported77923
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib + AnastrozoleAbemaciclibAnastrozoleTotal
American Indian or Alaska Native0000
Asian12161644
Native Hawaiian or Other Pacific Islander0101
Black or African American5128
White555755167
More than one race1113
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib + AnastrozoleAbemaciclibAnastrozoleTotal
Canada0314
Austria1041226
Netherlands1023
Belgium52411
United States26282680
Taiwan571123
South Korea57214
Italy43411
Germany56415
Spain1316837
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Abemaciclib + AnastrozoleAbemaciclibAnastrozoleTotal
0 (Fully Active)697063202
1 (Restricted, able to do light sedentary work)551020
Unreported0112
Ki67 at Baseline
Ki67 at Baseline(Percent Cells Positive)Abemaciclib + AnastrozoleAbemaciclibAnastrozoleTotal
Mean27.24 ± 13.5627.88 ± 12.1326.86 ± 12.3227.33 ± 12.63
08

Study locations

66 sites
  • Comprehensive Blood and Cancer Center
    Bakersfield, California 93309, United States
  • University of California-San Diego
    La Jolla, California 92037-0845, United States
  • SMO TRIO -Translational Research
    Los Angeles, California 90024, United States
  • UCLA Medical Center
    Los Angeles, California 90024, United States
  • Cancer Care Associates Medical Group
    Redondo Beach, California 90277, United States
  • Sansum Medical Research Foundation
    Santa Barbara, California 93105, United States
  • Central Coast Medical Oncology Corporation
    Santa Monica, California 93454, United States
  • Stanford University
    Stanford, California 94305, United States
  • SMO Pharmatech Oncology Inc
    Denver, Colorado 80203, United States
  • St Mary's Hospital Regional Cancer Center
    Grand Junction, Colorado 81501, United States
  • Holy Cross Hospital Inc.
    Fort Lauderdale, Florida 33308, United States
  • Memorial Regional Hospital/Joe Dimaggio Childrens Hospital
    Hollywood, Florida 33021, United States
  • Oncology and Radiation Associates
    Miami, Florida 33133, United States
  • Orlando Health, Inc
    Orlando, Florida 32806, United States
  • Florida Cancer Research Institute
    Plantation, Florida 33324, United States
  • Northeast Georgia Cancer Care, LLC
    Athens, Georgia 30607, United States
  • Georgia Regents University
    Augusta, Georgia 30912, United States
  • Kaiser Foundation Hospitals
    Honolulu, Hawaii 96819, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • University of Massachusetts Medical Center
    Worcester, Massachusetts 80203, United States
  • Nebraska Hematology-Oncology
    Lincoln, Nebraska 68506, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • St. Charles Health System
    Bend, Oregon 97701, United States
  • The West Clinic
    Germantown, Tennessee 38138, United States
  • Millennium Oncology
    Houston, Texas 77090, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Columbia Basin Hematology & Oncology
    Kennewick, Washington 99336, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Graz, 8036, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Innsbruck, 6020, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Wien, 1090, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Edegem, 2650, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Hasselt, 3500, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Namur, 5000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Yvoir, 5530, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Montreal, H4A 3J1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Ottawa, K1H 8L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Berlin, 13125, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Erlangen, 91054, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Essen, 45136, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Esslingen, 73730, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Freiburg, 79106, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Furth, 90766, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Heidelberg, 69120, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Ludwigsburg, 71640, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Tubingen, 72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Ulm, 89075, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Milano, 20141, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Napoli, 80131, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Padova, 35128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Piacenza, 29121, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Daegu, 41404, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Gangnam-gu, 06351, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Seodaemun-gu, 03722, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seongbuk-gu, 02841, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seongnam, 13496, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Songpa-gu, 05505, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Ulsan-si, 44033, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Maastricht, 6229 HX, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Rotterdam, 3015 GD, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Badajoz, 06080, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Lleida, 25198, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Madrid, 28034, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Malaga, 29010, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Changhua, 500, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Taichung, 40447, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Taipei, 100, Taiwan
09

References and documents

Publications

  • Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. Breast Cancer Res Treat. 2022 Apr;192(2):457-462. doi: 10.1007/s10549-022-06525-3. Epub 2022 Jan 25. PubMed 35076812 ↗
  • Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020 Feb 1;26(3):566-580. doi: 10.1158/1078-0432.CCR-19-1425. Epub 2019 Oct 15. PubMed 31615937 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Aug 2016 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 1 year 5 months after primary completion. A results delay was requested in Dec 2016.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2015
First posted
May 12, 2015
Start
Aug 2015
Primary completionActual
Aug 16, 2016
CompletionActual
Feb 12, 2018
Results delay requested
Dec 21, 2016
Results first posted
Jan 30, 2018
Last update
Jun 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02441946
Responsible party
Sponsor
First posted
May 12, 2015
Start date
Aug 2015
Primary completion
Aug 16, 2016
Completion
Feb 12, 2018
Results posted
Jan 30, 2018
Last update
Jun 17, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Anastrozole

Start the discussion